

Press release
Lund; Sweden, March 21, 2013

Christian W. Jansson is proposed as the new Chairman of the Board of Enzymatica

Christian W. Jansson, former President and CEO of KappAhl – a leading Swedish clothes retailer – has been proposed as the new Chairman of the Board of Enzymatica. The election of the Board Chairman will be dealt with at the AGM on 6th of May. Christian W. Jansson would replace Åke Larsson, who has not sought reelection.

“We are very gratified that Christian W. Jansson has accepted the proposal to be Board Chairman. His experience from the retail trade and publicly traded companies will be valuable now that Enzymatica is commercializing its operations via a broad-based market introduction of ColdZyme®Munspray and other products,” says Michael Edelborg Christensen, CEO at Enzymatica.

“Enzymatica is a highly exciting company which is now launching innovative products designed to prevent and treat a number of our most common illnesses, such as colds. I believe that that the company has considerable potential to succeed in building up robust operations both in Sweden and internationally,” notes Christian W. Jansson.

Christian W. Jansson is Chairman of the Board of Svensk Handel (Swedish Trade Federation) and Apoteket AB (major Swedish pharmacy chain) and is a member of the boards of Svenskt Näringsliv (Confederation of Swedish Enterprise), Bong AB, KappAhl AB, Europris AS and others. Christian W. Jansson has also been active in the Bonnier Dental Group, which is responsible both for global and European operations.

For more information on Enzymatica, contact:

Michael Edelborg Christensen, CEO at Enzymatica AB (publ), 0768-14 41 66,
michael.christensen@enzymatica.se

About Enzymatica AB (publ)

Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical devices based on patented enzyme technology. Enzymatica utilizes a marine enzyme, a cold-adapted trypsin derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica currently has two registered medical devices, PeriZyme chewing gum against diseases and ColdZyme CE oral spray for colds recently launched in pharmacies throughout the country.

About Enzymatica on the web

[Enzymatica's press room »](#)

[Enzymatica's website »](#)

[Enzymatica on LinkedIn »](#)

[Enzymatica on Twitter »](#)

[For Investors »](#)

[ColdZyme website »](#)

[ColdZyme on Facebook »](#)